At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 247 enrolled
Drug / intervention
Alendronate +2 moredrug
Likely dose
Alendronate 70 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment With Denosumab (AMG 162) and Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density
In Brief
A Phase 2 clinical trial evaluating Alendronate, Denosumab, and 1 other intervention for Postmenopausal Osteoporosis. Completed, enrolled 247 participants.
Detailed Summary
This study is structured to estimate the effect of denosumab, compared to placebo and alendronate, on several bone parameters.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPostmenopausal Osteoporosis
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 2006
Enrollment StartMay 2006
Primary CompletionMar 2008
Study CompletionAug 2008
TodayJul 2026
First PostedFeb 20, 2006
Enrollment StartMay 1, 2006
Primary CompletionMar 1, 2008
Study CompletionAug 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 20.4 years ago
Interventions
Alendronatedrug
Alendronate 70 mg PO QW
Denosumabdrug
denosumab 60 mg SC q 6 mos
Placebodrug
Placebo for alendronate and placebo for denosumab